Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Doxorubicin, and Prednisone in patients with Peripheral T-Cell lymphoma, NOS.

Statements

Source and description

Adcetris (brentuximab vedotin) [product monograph]. HC. Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.